Article from the Frankfurter Allgemeine Zeitung from December 24, 19:
Who Wants To Live Forever?
2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.
A Conversation About MetrioPharm AG’s Phase II Clinical Trial
MetrioPharm AG has just published Top Line Data for the Phase II clinical trial in psoriasis. Was the study a success?
Wolfgang Brysch: Yes, the study was clearly a success. We had a number of specific questions and were able to answer most of them...
A Conversation With the New MetrioPharm CFO Sven Zimmermann
You have been working in the life science and healthcare sector for more than fifteen years. What makes this work so appealing?
The sector has its own special challenges. On the one hand, the costs for drug development are significant and the development itself is highly regulated...
How safe is MP1032? And why is that so important to us?
Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032?
When I started working in medical research, m...
The connection between chronic inflammation and diseases of aging
Is there a problem with increasing life expectancy? If you look at the graph of average life years alone, the development over the last fifty years looks very positive. This graph shows a steady upward trend, especially in Western countries. People are getting older continuously.
There is, however, a second graph that has risen much slower: that of healthy life expectancy...
A Conversation with Barry Frankel, MetrioPharm’s new Senior Vice President Strategy and Business Development
Do you remember first hearing about MetrioPharm?
Yes, I do remember. I have a friend, who told me to take a look at this company. I reviewed their data and the first thing I liked was the unique profile of the MP1032 platform...
A report on the current projects of the MetrioPharm team
Timetables on the office walls, e-mails with long to-do lists and meetings of all project groups: The new year has started off busy. In order to move the MetrioPharm pipeline ahead as planned, the team is coordinating several major projects simultaneously.
One of the most important is the completion of the Phase II trial in the indication psoriasis...
The most frequently asked question in 2018: InflammAging
For this blog entry, we’ve been thinking: Is there a question that has been asked most frequently this year? And what does the answer say about our work at MetrioPharm?
The most frequently asked question clearly was: “Is MetrioPharm working on InflammAging?”
MetrioPharm at the ECTRIMS Conference in Berlin
In October you attended the ECTRIMS conference for MetrioPharm. What was your impression?
Dr. Sara Schumann: The conference is immense. This year there were more than 9000 participants who met in Berlin. One can say that this international conference is the most important forum for researchers and clinicians on multiple sclerosis (MS).
Dr. Astrid Kaiser: Many MS therapies already available today were presented. Of course, we can learn a lot from these post-marketing studies as they clearly show the advantages and disadvantages of currently available drugs.